There is increasing evidence reporting that as a common phenomenon in MetS relative diseases,
insulin resistance (IR) is regarded as an independent etiological factor and a warning indicator of
MetS occurrence. Therefore, for the special group (overweight or obesity), clinical regular monitoring
of IR is an important basis for the prevention and early intervention of MetS relative diseases. This
surveys reveals that human umbilical cord mesenchymal stem cells (HUC-MSCs)possess a kind of
potential: it may become a possible theraphy for IR in type 2 diabetes mellitus (T2DM) and related
diseases. Specific emphasis is focused on evaluating the improvement IR function of HUC-MSCs under
the background of development in vitro and in vivo. Next, the action mechanisms of HUC-MSCs is
discussed, and some of their advantages and disadvantages in the course of clinic application are presented.
The final section highlights the application of HUC-MSCs in T2DM and relative diseases at
this stage. Up to now, although many questions remain unresolved, we still consider that HUC-MSCs
is one of the best therapy ameliorating IR in the future.
Keywords: Human umlilical cord mesenchymal stem cells, insulin resistance, T2DM, clinical implication, overweight, obesity.
Rights & PermissionsPrintExport